argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update. Investors can access the live webcast and a replay, available for about one year, via the Investors section of the argenx website or join by phone using access code 3810049 and the listed country-specific dial-in numbers.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
In the Jul 16 session, ARGX declined 0.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Earnings date notice | Neutral | +0.7% | Scheduled Q1 2026 results release and investor call with webcast access. |
| Feb 19 | Earnings date notice | Neutral | +0.2% | Announced full-year 2025 results date and fourth quarter business update call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date announcements for argenx have been followed by modestly positive next-day moves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
July 16, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below:
Belgium 32 2290 4635
France 33 172 001717
Netherlands 31 20 795 2683
United Kingdom 44 203 393 1560
Japan 81 3 4520 9761
Switzerland 41 43 210 51 68
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
